Beam Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Beam Therapeutics Inc. (BEAM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $28.41 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $27.47, a 6.18% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $25.87, a 4.86% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $24.67, a 42.72% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $43.07, a 37.70% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $24.51, a 1.17% decline from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $24.80, a 37.41% decline from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $39.62, a 34.78% decline from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $60.75, a 31.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.41 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $27.47 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $24.51 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $24.45 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $24.61 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $25.87 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $24.80 10-K · filed 2025-02-25 | |||
| 2024-09-30 | $24.74 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $24.60 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $24.67 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $39.62 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $40.28 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $41.69 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $43.07 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $60.75 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $62.32 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $63.17 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $69.13 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $88.15 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $88.57 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $86.38 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $80.89 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $22.47 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $19.40 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $18.39 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $17.15 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |